The proviral integration moloney murine leukaemia virus (Pim) kinases, consisting of Pim-1, Pim-2 and Pim-3, are involved in the control of cell growth, metabolism and differentiation. Pim kinases are emerging as important mediators of adipocyte differentiation. AZD1208 is a pan-Pim kinase inhibitor and is known for its anti-cancer activity. In this study, we investigated the effect of AZD1208 on adipogenesis and --
Adipocyte differentiation, also called adipogenesis, is the process during which fibroblast-like preadipocytes develop into mature adipocytes. 5 Adipocyte differentiation is controlled by the family of CCAAT/enhancer-binding proteins (C/EBPs) and peroxisome proliferator-activated receptors (PPARs) 6, 7 and Janus-activated protein kinase/signal transducer and activator of transcription (STAT) signalling complexes. 8 In addition, the expression and/or activity of lipogenic enzymes, such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), and lipid droplet (LD)-associated proteins, like perilipin A, are required for adipocyte differentiation. [9] [10] [11] [12] A number of researchers reported about the involvement of cAMP-activated protein kinase (AMPK), protein kinase A (PKA), extracellular signalregulated protein kinase-1/2 (ERK-1/2) and adenosine 3 0 ,5 0 -cyclic monophosphate (cAMP) in the control of adipocyte differentiation. 10, 13, 14 Lipolysis is defined as the hydrolytic cleavage of ester bonds in triglyceride (TG), resulting in the generation of fatty acids and glycerol. 15 Hormone-sensitive lipase (HSL) is a key enzyme in the mobilization of fatty acids from stored TG 16 and is phosphorylated (activated) by PKA, ERK-1/2 and cAMP. 16, 17 Thus, any compound that inhibits excessive adipogenesis and/or promotes lipolysis in adipocytes could be a therapeutic option against obesity.
The proviral integration site for moloney murine leukaemia virus (Pim) kinases, consisting of Pim-1, Pim-2 and Pim-3, are active serine (S)/threonine (T) kinases that are constitutively expressed and are involved in the control of cell cycle, proliferation, and survival of normal and cancer cells. 18 Due to the oncogenic/pro-survival role in cancer biology, Pim kinases are recognized an interesting target for anti-cancer therapy. However, recent evidence suggests Pim kinases as important mediators of adipocyte differentiation, with Pim-2 considerably expressed in adipocytes, 19 and the expression of Pim-1 in adipocytic neoplasm as a marker of adipocytic differentiation. 20 We have recently shown that a pan-Pim kinase inhibitor SGI-1776 blocks adipogenesis in differentiating 3T3-L1 cells by reducing the expression and/or phosphorylation levels of C/EBP-a, PPAR-c, FAS and STAT-3. 21 Thus, inhibition of Pim kinases could be a novel therapeutic path against obesity.
AZD1208 is a thiazolidine that is highly selective for all Pim isoforms 22 and is known for its anti-cancer activity. 23, 24 As of now, neither the anti-obesity effect nor the mode of action of AZD1208 in adipocytes is reported. This is the first study reporting the antiadipogenic and lipolytic effects of AZD1208 on 3T3-L1 adipocytes through control of the expression and/or phosphorylation levels of C/EBP-a, PPAR-c, FAS, ACC, perilipin A, STAT-3, AMPK and HSL.
| MATERIALS AND METHODS

| Drugs and antibodies
AZD1208 was purchased from Selleckchem (Houston, TX, USA).
Primary antibodies for anti-C/EBP-a, anti-PPAR-c, anti-phospho
anti-p-Bad (S112), anti-Bad as well as secondary goat anti-rabbit and goat antimouse IgG antibodies were purchased from Santa Cruz Biotechnology (Delaware, CA, USA The cells were fed every other day with DMEM containing 10% FBS in the presence or absence of AZD1208 until day 8.
| Oil red O staining
On day 8 of differentiation, the mock or AZD1208-treated 3T3-L1 cells were washed with PBS, fixed with 10% formaldehyde for 2 hour at room temperature (RT), washed with 60% isopropanol and dried. The fixed cells were stained with Oil Red O working solution (Sigma) for 1 hour at RT and washed with distilled water. LDs were observed using a light microscopy (Nikon, TS100, Japan).
| Cell count analysis
3T3-L1 preadipocytes seeded in 24-well plates were similarly grown under the above-mentioned differentiation conditions. On day 8 of differentiation, the mock or AZD1208-treated 3T3-L1 cells, which cannot be stained with trypan blue dye, was counted under microscope. The cell count assay was done in triplicates.
Data are mean AE standard error (SE) of three independent experiments.
| Quantification of intracellular TG contents by
AdipoRed assay 
| Quantitative real-time RT-PCR
Total cellular RNA in the mock or AZD1208-treated 3T3-L1 cells was isolated with the RNAiso Plus (Takara, Kusatsu, Shiga, Japan).
Three micrograms of total RNA were reverse transcribed using a random hexadeoxynucleotide primer and reverse transcriptase. Single- 
| Statistical analysis
Cell count analysis was done in triplicates and repeated three times. Data were expressed as mean AE SE. The significance of difference was determined by one-way ANOVA (Laerd Statistics, Chicago, IL, USA). All significance testing was based upon a P value of <.05.
3 | RESULTS
| AZD1208 inhibits lipid accumulation and reduces TG contents in differentiating 3T3-L1 cells
To see the drug's anti-adipogenic effect, we first determined LDs. The AZD1208's lipid-reducing effect was also confirmed by light microscopy ( Figure 1B , lower panels). We then examined whether AZD1208 reduces TG contents by an AdipoRed assay.
AZD1208 also remarkably decreased the levels of TG in a dosedependent manner ( Figure 1C ). We finally looked at whether AZD1208 at the doses tested has cytotoxicity using cell count analysis. AZD1208 at the doses applied was not cytotoxic to 3T3-L1 cells; rather, AZD1208 at 20 and 40 lmol L À1 enhanced the cell survival ( Figure 1D ). In consequence of strong inhibitory effects on lipid accumulation and TG synthesis with no cytotoxicity, the concentration of 40 lmol L À1 of AZD1208 was selected for more studies. Figure 2G ,H,I, respectively.
| AZD1208 down-regulates the expressions of FAS, perilipin A and leptin in differentiating 3T3-L1 cells
We next investigated the effect of AZD1208 on expressions of FAS and perilipin A in differentiating 3T3-L1 cells. AZD1208 greatly suppressed protein levels of FAS and perilipin A on days 5 and 8 (Figure 3A) . Moreover, AZD1208 reduced perilipin A, but not FAS, mRNA levels on days 2, 5 and 8 ( Figure 3B) Figure 3C,D) . The densitometry data of Figure 3C ,D are shown in Figure 3E ,F, respectively. Control S6 protein expression remained unchanged under these experimental conditions.
3.4 | AZD1208 increases AMPK and LKB-1 phosphorylation while decreases ACC phosphorylation in differentiating 3T3-L1 cells AMPK is a major regulator of energy metabolism, and its activation (phosphorylation) leads to inhibition of adipogenesis. 26 We thus F I G U R E 1 Effects of AZD1208 on adipogenesis and cell growth in differentiating 3T3-L1 cells. A, The experimental scheme of 3T3-L1 preadipocyte differentiation. B-D, 3T3-L1 preadipocytes were induced to differentiate with induction medium in the presence or absence of AZD1208 for 8 days. On day 8, cellular lipid contents were assessed by Oil Red O staining B, Phase-contrast images of the cells were also taken after the treatment (lower panels in (B). On day 8, cellular TG contents were quantified by AdipoRed assay (C), respectively. Values are mean AE standard error (SE) of data from three independent experiments with three replicates. *P < .05 vs control. On day 8, AZD1208-treated 3T3-L1 cells, which cannot be stained with trypan blue dye, were counted under microscope (D). The cell count assay was done in triplicates. Data are mean AE SE of three independent experiments. *P < .05 vs control PARK ET AL.
| 2491 probed whether AZD1208 modulates AMPK phosphorylation in differentiating 3T3-L1 cells. Notably, AZD1208 increased AMPK phosphorylation on days 2, 5 and 8 ( Figure 4A ). AZD1208 did not affect total AMPK protein levels. ACC is a best-known downstream effector of AMPK and is involved in the biosynthesis of fatty acids. 27 There was a time-dependent increase in ACC phosphorylation during 3T3-L1 preadipocyte differentiation. Yet, ACC phosphorylation was largely repressed by AZD1208 at the times tested. In addition, ACC total protein levels were reduced in the presence of AZD1208 on days 2 and 5, but not 8. Considering that liver kinase B-1 (LKB-1) is the main kinase to induce AMPK phosphorylation, 28 we next measured whether LKB-1 protein is expressed and activated (phosphorylated) in differentiating 3T3-L1 cells and is regulated by AZD1208. In the absence of AZD1208, there were high levels of phosphorylated analysis in triplicate experiments on day 8, respectively. G and H, the densitometry data of (D) and (E), respectively. I, The densitometry result of (F). *P < .05 compared to the value of AZD1208 free control on the indicated day 
| AZD1208 decreases intracellular levels of ATP in differentiating 3T3-L1 cells
AMPK phosphorylation is also induced by alterations in the intracellular AMP/ATP ratio. 29 We thus examined whether AZD1208 affects intracellular ATP levels in differentiating 3T3-L cells. In this study, 2-deoxyglucose (2-DG), a glucose mimetic that lowers intracellular ATP levels, was used as a control. As shown in Figure 5A -C, 2-DG substantially lowered cellular ATP contents on days 2, 5 and 8 of adipocyte differentiation. AZD1208 also had an ability to slightly reduce levels of cellular ATP on days 2, 5 and 8 of adipocyte differentiation.
| AZD1208 enhances levels of Pim-3 protein in differentiating 3T3-L1 cells
We next studied whether Pim kinases are expressed and AZD1208 alters their expression in differentiating 3T3-L1 cells. Interestingly, substantial expression levels of Pim-3, but not Pim-2 and Pim-1, protein were observed on days 2, 5 and 8 ( Figure 6A ). There was also substantial expression of Pim-3 mRNA on days 2, 5 and 8
( Figure 6B ). Strikingly, AZD1208 enhanced levels of Pim-3 protein without affecting mRNA expression on days 2, 5 and 8. Pim kinases phosphorylate downstream effectors, such as Bcl-2-associated death promoter (Bad) protein on three serine (S) residues, including S112, S136 and S155. 30, 31 We then looked at whether Bad is expressed and phosphorylated on S112, and AZD1208 affects it in differentiating 3T3-L1 cells. 
| AZD1208 promotes lipolysis and HSL phosphorylation in differentiated 3T3-L1 adipocytes
We next investigated the effect of AZD1208 on lipolysis in differen- 
| DISCUSSION
Pim kinases are known mediators of adipocyte differentiation.
AZD1208 is a pan-Pim kinase inhibitor and is known for its anti- AMPK is a key regulator of energy metabolism and balance. 38 It is a heterotrimeric protein kinase consisting of a catalytic a subunit and regulatory b and c subunits. Recent evidence indicates that intracellular increase in the AMP/ATP ratio induces AMPK phosphorylation on T172 within the a subunit by liver kinase B1 (LKB1). 39 A number of studies also have demonstrated that activation of AMPK inhibits ATP-consuming anabolic processes while activates ATPproducing catabolic processes, 40, 41 and the effects are mediated via the phosphorylation of metabolic enzymes, such as ACC. 42 There is also evidence that activation of AMPK induces ACC phosphorylation on S79, which strictly regulates the enzyme during fatty acid synthesis for malonyl-CoA production, and phosphorylated ACC lacks its activity to synthesize fatty acids. 26, 43 Interestingly, the Pim kinasemediated regulation of AMPK activity and energy metabolism has been previously proposed, with the facts that a novel Pim kinase inhibitor SMI-4a induces activation of AMPK via increased AMP/ ATP ratio in mouse embryonic fibroblasts deficient for all Pim isoforms. 44 Given that AZD1208 increases AMPK phosphorylation but Our recent findings that a pan-Pim kinase inhibitor SGI-1776 suppresses adipogenesis 21 and a meridianin C derivative, which has Pim kinase inhibitory activity, 45 blocks adipogenesis 46 a role in the cell growth/survival. 23, 24, 44 16, 17 it is plausible that AZD1208 exerts its lipolytic effect via the PKA-dependent HSL activation.
In summary, this is the first report demonstrating that AZD1208
has anti-adipogenic and lipolytic effects on 3T3-L1 adipocytes through control of the expression and/or phosphorylation levels of PPAR-c, C/EBP-a, FAS, ACC, perilipin A, STAT-3, AMPK and HSL.
Even if important questions such as anti-adipogenic and lipolytic effects of AZD1208 on obese animal models remain to be resolved, the present findings advocate AZD1208 as a potential therapeutics for the treatment of obesity.
